로딩 중…
지수 로딩 중…
AbClon Inc.
174900· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩29,800-5.70%
2026-06-19
Price Chart
AbClon Inc.+179.81%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 594.57B KRW |
| Revenue | 4.74B KRW |
| Net Income | -14.71B KRW |
| Total Assets | 68.43B KRW |
| Net Assets | 58.28B KRW |
| Employees | 63 |
| Value | |
| P/B | 10.20x |
| P/S | 125.55x |
| FCF Yield | -2.43% |
| Profitability | |
| ROE | -25.24% |
| ROA | -21.50% |
| Op. Margin | -315.38% |
| Revenue Growth | 5.22% |
| Financial Health | |
| Debt Ratio | 117.43% |
| Total Debt | 7.00B KRW |
| FCF | -14.42B KRW |
| Cash | 36.11B KRW |
| Current Ratio | 4.89x |
| Performance | |
| 1Y Return | 179.81% |
| 1M Return | -16.99% |
| From 52W High | -68.89% |
| 1Y MDD | -67.68% |
| Trading | |
| Volume | 158,460 shares |
| Foreign Own. | 11.54% |
| Per Share | |
| EPS | -742 KRW |
| BPS | 2,840 KRW |
Company Info
AbClon, established in 2010 and headquartered in Guro-gu, Seoul, is a bio-venture focused on antibody new drug development, manufacturing, and sales, specially listed on KOSDAQ in 2017. The company utilizes platforms such as NEST, AffiMab, and CAR-T, maintaining a research network with Atlas in Sweden. AbClon licensed AC101, developed with NEST technology, to Shanghai Henlius, and its CAR-T therapeutic AT101 is currently in Phase 2 clinical trials. It aims to strengthen its immune cell therapy presence through a partnership with Chong Kun Dang in 2025.